Back to contents

Managing advanced liver disease

Over years or decades, chronic hepatitis B or C can cause serious liver disease including advanced fibrosis, cirrhosis and liver cancer. As scar tissue or tumours replace normal cells, liver function declines and blood flow through the liver is blocked. When the liver becomes unable to carry out its crucial functions this is known as decompensated liver disease.

People with advanced liver damage may not be able to process HIV medications or other drugs properly, and they therefore may need dose adjustments or a change in their drug combination. Overall, however, people living with HIV who have serious liver disease appear to do better when taking antiretroviral treatment.

Liver damage can lead to a wide range of health problems including internal bleeding in the stomach and oesophagus, swelling of the abdomen (ascites), poor blood clotting, brain impairment (hepatic encephalopathy) and increased susceptibility to infections. Some of these are due to the build-up of toxins that the liver can no longer filter out of the blood.

Liver cancer, or hepatocellular carcinoma, is commonly diagnosed late and is difficult to treat. Small tumours can sometimes be surgically removed. Other treatments include localised or whole-body chemotherapy, radiation and burning or freezing tumours. These methods can relieve symptoms and sometimes improve survival, but they usually do not cure liver cancer.

Because these treatments work best if liver cancer is diagnosed early, people at risk should be screened regularly. Current guidelines recommend ultrasound scans every six months for anyone with hepatitis B and for people with hepatitis C who have cirrhosis.

Various medications and procedures are used to manage symptoms of advanced liver disease, but mostly these do not improve the long-term health of the liver. Successful treatment of hepatitis B or C can stop liver disease from worsening and the liver may be able to partially heal itself. But advanced liver damage is often permanent, which is why it is important to start hepatitis treatment early, before it occurs.

Liver transplants

If your liver becomes so damaged that it cannot repair itself and is likely to fail completely, you may need to consider a liver transplant.

Transplants may use a donated liver from a person who has died or a piece of liver from a living donor, since liver tissue can regenerate itself. Unfortunately, donated livers are in short supply and most people who need a transplant will have to spend time on a waiting list.

Liver allocation is based on a scoring system. Donated livers go first to people who need them most but are not yet so sick that they are unlikely to benefit. Liver disease can progress rapidly in people living with HIV, so people with signs of decompensated cirrhosis or liver cancer should be referred to a transplant centre early.

The hepatitis B vaccine and an HBV antibody preparation (HBV immunoglobulin or HBIG) can prevent the new liver graft from becoming infected with HBV.

HCV almost always infects the new liver soon after a transplant. Curing hepatitis C before the transplant will prevent this from happening, and successful treatment can sometimes improve liver function enough that a person no longer needs a transplant. But people with severe decompensated liver disease may have trouble tolerating treatment and have a lower likelihood of being cured.

Alternatively, direct-acting antiviral (DAA) treatment can be started after a transplant. Most transplant recipients can be cured with available regimens. However, some DAAs have not been well studied in this population and some of them can interact with immune-suppressing drugs used to prevent organ rejection.

Studies have found that people with well-controlled HIV can do as well after a liver transplant as HIV-negative people, although those with hepatitis C co-infection do somewhat less well.

After a successful liver transplant, you will need to take immune-suppressing medication for the rest of your life to stop your body from rejecting the new liver. You will still have to take HIV treatment as well, and it is important to avoid or manage interactions with antiretrovirals.

HIV & hepatitis

Published December 2017

Last reviewed December 2017

Next review December 2020

Contact NAM to find out more about the scientific research and information used to produce this booklet.

Hepatitis information

For more information on hepatitis visit infohep.org.

Infohep is a project we're working on in partnership with the European Liver Patients Association (ELPA) and the World Hepatitis Alliance.

Visit infohep.org >
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.